The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | The role of MRD in AML
Jacqueline Cloos, PhD, of Amsterdam UMC, Amsterdam, The Netherlands, talks on the role of measurable residual disease (MRD) as a prognostic factor in the management of acute myeloid leukemia (AML). MRD is a small number of leukemic cells that remain after treatment, which is the major cause of relapse in cancer patients. Prof. Cloos talks on the strengths of MRD as a prognostic factor for the early identification or patients with AML who are at higher risk of relapse during therapy. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Jacqueline Cloos, PhD, has received institutional research funding from Genentech, BD Biosciences, Novartis, Takeda Pharmaceuticals and Merus; royalties from BD Biosciences and Navigate; and MRD assessments from DC Prime, Helsinn, Janssen, Merus and Novartis.
